Gilteritinib for treating relapsed or refractory acute myeloid leukaemia – Final appraisal document

In DRAFT guidance, gilteritinib monotherapy is recommended as an option for treating relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults only if the company provides gilteritinib according to the commercial arrangement.

SPS commentary:

The draft guidance states that it should not be given as maintenance therapy after a haematopoietic stem cell transplant. The appeal period for this appraisal will close on 30th July 2020 and final guidance is expected to be published in August 2020.


National Institute for Health and Care Excellence